Cancer Immunotherapy: An Update: Abul K. Abbas Ucsf Abul - Abbas@ucsf - Edu

1
Cancer immunotherapy: an update
Abul K. Abbas
UCSF
Abul.Abbas@ucsf.edu
General principles
2
• The immune system recognizes and reacts

against cancers
• The immune response against tumors is often

dominated by regulation or tolerance
– Evasion of host immunity is one of the hallmarks of
cancer
• Some immune responses promote cancer growth
• Defining the immune response against cancers

will help in developing new immunotherapies
T cell responses to tumors 3
4
Cross-presentation of tumor antigens

Immune phenotypes that predict better survival 5
Analysis of 124
published articles on
correlation of T cell
subsets and
prognosis of 20
cancer types
Fridman et al. Nat Rev Cancer 12:298, 2012

6
Types of tumor antigens

• Most tumor antigens that elicit immune
responses are neoantigens
– Not present normally, so no tolerance
– Produced by mutated genes that may be involved
in oncogenesis (driver mutations) or reflect
genomic instability (passenger mutations)
– In tumors caused by oncogenic viruses (HPV,
EBV), neoantigens are encoded by viral DNA
• Some are unmutated proteins (tyrosinase,

cancer-testis antigens)
– Derepressed (epigenetic changes), over-
expressed
Identification of tumor neoantigens 7
Next gen sequencing and/or

RNA-seq
Identification of HLA-
binding peptides
MHC-peptide multimer
and/or functional assays
Ton N. Schumacher, and Robert D. Schreiber Science 2015;348:69-74

Immune responses that promote tumor growth 8
M2
Coussens et al. Science 339:286, 2013

9
The history of cancer immunotherapy: from empirical
approaches to rational, science-based therapies
Treatment of
cancer with
bacterial Treatmen FDA approval of
products t of Adoptive Adoptive sipuleucel-T (DC FDA approval
(“Coley’s bladder cell T cell vaccine) in of anti-PD1
toxin”) cancer therapy therapy prostate cancer for melanoma
with BCG
1863 1898 1957 1976 1983 1985 1991, 4 2002 2009 2010 2011 2014
Description of Cancer IL-2 Discovery HPV FDA approval of Breakthrough

immune immunotherapy of human vaccination anti-CTLA4 status for
infiltrates in surveillance for tumor in VIN (ipilumimab) for CAR-T cells
tumors by hypothesis cancer antigens melanoma in leukemia
Virchow (Burnet, (Boon,
Thomas) others)
10
11
Passive immunotherapy
Chimeric antigen receptors 12
• Remarkable
success in B cell
acute leukemia
(targeting CD19);
up to 90%
complete remission
• Risk of cytokine
storm
• Outgrowth of
antigen-loss
variants of
tumors?
13
Development of chimeric antigen receptors

14
Limitations and challenges of CAR-T

cell therapy
• Cytokine storm – many T cells respond to
target antigen
– Requires anti-inflammatory therapy (anti-IL-6R)
– Risk of long-term damage (especially brain)
• Unclear how well it will work against solid
tumors
– Problem of T cells entering tumor site
• Will tumors lose target antigen and develop
resistance?
• Technical and regulatory challenges of
producing genetically modified CAR-T cells for
each patient
– Prospect of gene-edited “universal” CAR-T cells?
Limitations and challenges of CAR-T
cell therapy -- 2
• Exhaustion of transferred T cells
– Use CRISPR gene editing to delete PD-1 from T cells
– Increased risk of autoimmune reactions from endogenous
TCRs
– Use CRISPR to delete TCRs
– Result is PD-1- T cells expressing tumor-specific CAR
16
Dendritic cell vaccination

17
Blocking CTLA-4 promotes tumor rejection:

CTLA-4 limits immune responses to tumors
Administration of antibody that blocks CTLA-4 in

tumor-bearing mouse leads to tumor regression
Checkpoint blockade: Removing the brakes on
18
the immune response
Anti-CTLA-4 antibody is approved for tumor

immunotherapy (enhancing immune responses
against tumors)
Even more impressive results with anti-PD-1 in
cancer patients
Checkpoint blockade for cancer immunotherapy
Priming phase
Effector phase
Checkpoint blockade
20
Why do tumors engage CTLA-4 and PD-1?
• CTLA-4: tumor induces low levels of B7

costimulation  preferential engagement of
the high-affinity receptor CTLA-4
• PD-1: tumors may express PD-L1
• Remains incompletely understood

– These mechanisms do not easily account for all
tumors
21
Is checkpoint blockade more effective

than vaccination for tumor therapy?
• Tumor vaccines have been tried for many
years with limited success
• Immune evasion is a hallmark of cancer

– Multiple regulatory mechanisms
• Vaccines have to overcome regulation

– Tumor vaccines are the only examples of
therapeutic (not prophylactic) vaccines
– Vaccination after tumor detection means
regulatory mechanisms are already active
The landscape of T cell activating and 22
inhibitory receptors
Inhibitory receptors Activating receptors
(coinhibitors) (costimulators)
CTLA-4
CD28
PD-1 ICOS
TIM-3
OX40
TCR
T cell
TIGIT GITR
LAG-3 CD137 (4-1BB)
BTLA CD27
23
Targeting inhibitory receptors for

cancer immunotherapy
• Blocking inhibitory receptors induces tumor
regression
– Partial or complete responses in up to 40%
– Biomarkers for therapeutic responses?
• May be more effective than vaccination

– Vaccines have to overcome tumor-induced
regulation/tolerance
• Adverse effects (inflammatory autoimmune

reactions)
– Typically manageable (risk-benefit analysis)
Combination strategies for cancer
24
immunotherapy
• Combinations of checkpoint blockers, or bispecific

antibodies targeting two checkpoints
• Already done with CTLA-4 and PD-1
• Checkpoint blockade (anti-PD1 or -CTLA-4) +

vaccination (DCs presenting tumor antigen)
• Checkpoint blockade + agonist antibody specific for

activating receptor
• Checkpoint blockade + kinase inhibitor to target

oncogene
25
Checkpoint blockade: prospects and

challenges
• Exploiting combinations of checkpoints

– Poor biology underlying choice of combinations
to block
– Difficult to reliably produce agonistic
antibodies
• Typically, 20-40% response rates; risk

of developing resistance?
Checkpoint blockade: prospects and
26
challenges
• Exploiting combinations of checkpoints
• Typically, 20-40% response rates; risk of developing
resistance?
• Possible biomarkers of response vs
resistance:
– Nature of cellular infiltrate around tumor
– Expression of ligands for inhibitory receptors
(e.g. PD-L1) on tumor or DCs
– Frequency of neoantigens (HLA-binding
mutated peptides) in tumors from different
patients
– Frequency of tumor-specific “exhausted” T
cells

Cancer Immunotherapy: An Update: Abul K. Abbas Ucsf Abul - Abbas@ucsf - Edu

Uploaded by

Copyright:

Available Formats

Cancer Immunotherapy: An Update: Abul K. Abbas Ucsf Abul - Abbas@ucsf - Edu

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Cancer Immunotherapy: An Update: Abul K. Abbas Ucsf Abul - Abbas@ucsf - Edu

Uploaded by

Copyright:

Available Formats

1

Cancer immunotherapy: an update

• The immune system recognizes and reacts

• The immune response against tumors is often

• Some immune responses promote cancer growth

• Defining the immune response against cancers

Cross-presentation of tumor antigens

Fridman et al. Nat Rev Cancer 12:298, 2012

Types of tumor antigens

• Some are unmutated proteins (tyrosinase,

Next gen sequencing and/or

Ton N. Schumacher, and Robert D. Schreiber Science 2015;348:69-74

Coussens et al. Science 339:286, 2013

Description of Cancer IL-2 Discovery HPV FDA approval of Breakthrough

Development of chimeric antigen receptors

Limitations and challenges of CAR-T

Dendritic cell vaccination

Blocking CTLA-4 promotes tumor rejection:

Administration of antibody that blocks CTLA-4 in

the immune response

Anti-CTLA-4 antibody is approved for tumor

Why do tumors engage CTLA-4 and PD-1?

• CTLA-4: tumor induces low levels of B7

• PD-1: tumors may express PD-L1

• Remains incompletely understood

Is checkpoint blockade more effective

• Immune evasion is a hallmark of cancer

• Vaccines have to overcome regulation

LAG-3 CD137 (4-1BB)

Targeting inhibitory receptors for

• May be more effective than vaccination

• Adverse effects (inflammatory autoimmune

• Combinations of checkpoint blockers, or bispecific

• Checkpoint blockade (anti-PD1 or -CTLA-4) +

• Checkpoint blockade + agonist antibody specific for

• Checkpoint blockade + kinase inhibitor to target

Checkpoint blockade: prospects and

• Exploiting combinations of checkpoints

• Typically, 20-40% response rates; risk

You might also like

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.